CMRX Chimerix, Inc.

4.50
-0.07  -2%
Previous Close 4.57
Open 4.58
Price To book 0.81
Market Cap 209.93M
Shares 46,651,000
Volume 327,175
Short Ratio 5.77
Av. Daily Volume 366,638

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b to be initiated late 2017.
Brincidofovir
BK virus
Phase 2b to be initiated late 2017.
Brincidofovir
Cytomegalovirus (CMV)
Phase 3 interim analysis released May 2016. Final data released February 22, 2017.
Brincidofovir - Advise trial
Adenovirus Infection
Phase 3 discontinued following poor data from SUPPRESS trial
Brincidofovir - SURPASS
Cytomegalovirus (CMV) infection
Phase 3 endpoints not met December 2015
Brincidofovir - SUPPRESS
Cytomegalovirus (CMV) infection following an allogeneic hematopoietic stem cell transplant (HSCT)
Phase 3 discontinued following poor data from SUPPRESS trial
Brincidofovir - SUSTAIN
Cytomegalovirus (CMV) infection